a2 Milk Secures China Regulatory Approval and Plans $300 Million Dividend
The a2 Milk Company has clinched final Chinese regulatory approval to rebrand infant formula products under its flagship a2™ label, completing a pivotal acquisition step. The company plans to launch these products later in 2026 and is poised to declare a $300 million special dividend.
- SAMR approval finalises China label product transition
- Acquisition of a2 Pokeno facility now irreversible
- Product launch slated for later in 2026
- Board intends $300 million fully franked special dividend
- Approval supports China growth and supply chain transformation
Regulatory Approval Unlocks China Market Potential
The a2 Milk Company (NZX:ATM, ASX:A2M) has secured a crucial green light from China's State Administration for Market Regulation (SAMR) to transfer two infant milk formula product registrations to the a2™ brand. This regulatory milestone completes the acquisition process for the a2 Pokeno manufacturing facility, a strategic asset underpinning the company's China ambitions.
With this approval, a2 Milk can no longer unwind the acquisition, cementing its commitment to expanding its footprint in one of the world’s largest infant formula markets. The company confirmed that product launches under the a2™ brand will proceed as planned later this year, maintaining the timeline and financial forecast initially outlined at acquisition.
Strategic Implications for Growth and Supply Chain
Managing Director David Bortolussi highlighted that SAMR’s approval is a "significant milestone" in a2 Milk’s China growth strategy and supply chain transformation. The move is expected to drive long-term growth in the core infant milk formula segment through enhanced market access and innovation.
This regulatory endorsement also accelerates the development of advanced nutritional manufacturing capabilities in New Zealand, enabling a2 Milk to capture incremental brand value and improve vertical margin control. The company’s focus on supply chain resilience has been under scrutiny, especially after recent challenges that affected delivery and margins earlier this year.
Special Dividend Signals Confidence
Following the regulatory clearance, the a2 Milk Board plans to convene soon to declare a $300 million special dividend. This payout is expected to be fully franked and unimputed, reflecting strong cash generation and confidence in the company’s financial position post-acquisition.
While the exact timing and payment details remain pending, the announcement signals a shareholder-friendly approach amid ongoing efforts to stabilise supply chains and capitalise on growth opportunities in China. This move may also help offset some investor concerns following earlier share price volatility linked to supply chain uncertainties and analyst downgrades.
Bottom Line?
With regulatory hurdles cleared and a substantial special dividend on the horizon, a2 Milk is poised to reinforce its China strategy, watch for product launch execution and dividend timing to gauge momentum.
Questions in the middle?
- How will the upcoming product launches perform amid ongoing supply chain challenges?
- What impact will the $300 million special dividend have on a2 Milk’s capital allocation strategy?
- Can a2 Milk sustain growth in China given recent geopolitical and logistical headwinds?
